Vivos Therapeutics Inc Aktie News

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Brad Amman - CFO Kirk Huntsman - Chairman and CEO Conference Call Participants Do Kim - Water Tower Research Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone. And welcome to the Vivos Therapeutics First Quarter 2025 Earnings Call.

LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate t...

By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-in...

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company Participants Bradford Amman - CFO, Treasurer & Secretary Kirk Huntsman - Co-Founder, Chairman & CEO Conference Call Participants Guyn Kim - Water Tower Research Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vi...

Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commerciali...

LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate...

Vivos Therapeutics (NASDAQ:VVOS) announced an expansion of its strategic marketing and distribution alliance with Rebis Health into two additional locations in Colorado. The company said initial data from the partnership showed that patients prefer Vivos CARE as a treatment for obstructive sleep apnea (OSA) nearly two to one over continuous positive airway pressure (CPAP) therapy, the current s...

Vivos Therapeutics (NASDAQ:VVOS) has announced definitive agreements for a registered direct offering and concurrent private placement expected to generate up to $6.9 million in gross proceeds The medical device company, which specializes in treatments for sleep-related breathing disorders, said the offering involves the sale of 709,220 shares at $4.935 per share, priced at-the-market under Nas...